{'52WeekChange': -0.2348091,
 'SandP52WeekChange': None,
 'address1': '4 Stamford Plaza',
 'address2': '9th Floor 107 Elm Street',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 17.5,
 'askSize': 800,
 'averageDailyVolume10Day': 321712,
 'averageVolume': 513780,
 'averageVolume10days': 321712,
 'beta': 1.943417,
 'beta3Year': None,
 'bid': 17.13,
 'bidSize': 1000,
 'bookValue': 3.434,
 'category': None,
 'circulatingSupply': None,
 'city': 'Stamford',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 17.52,
 'dayLow': 16.85,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -5.798,
 'enterpriseToRevenue': 29.08,
 'enterpriseValue': 686209408,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 16.954714,
 'fiftyTwoWeekHigh': 26.67,
 'fiftyTwoWeekLow': 8.88,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 42518899,
 'forwardEps': -2.46,
 'forwardPE': -6.9695125,
 'fromCurrency': None,
 'fullTimeEmployees': 67,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.025120001,
 'heldPercentInstitutions': 0.68982005,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': 1389830400,
 'lastSplitFactor': '1:2',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/caratherapeutics.com',
 'longBusinessSummary': 'Cara Therapeutics, Inc., a clinical-stage '
                        'biopharmaceutical company, focuses on developing and '
                        'commercializing chemical entities with a primary '
                        'focus on pruritus and pain by selectively targeting '
                        'kappa opioid receptors in the United States. The '
                        'company is developing product candidates that target '
                        "the body's peripheral nervous system and immune "
                        'cells. Its lead product candidate includes KORSUVA '
                        '(CR845/ difelikefalin) injection, which is in Phase '
                        'III clinical trial for the treatment of patients with '
                        'moderate-to-severe chronic kidney disease-associated '
                        'pruritus (CKD-aP) undergoing hemodialysis. The '
                        'company is also developing Oral KORSUVA '
                        '(CR845/difelikefalin), which has completed Phase II '
                        'clinical trial for the treatment of pruritus in stage '
                        'III-V CKD patients; in Phase II clinical trial for '
                        'treating pruritus chronic liver disease; and in Phase '
                        'II clinical trial for the treatment of pruritus '
                        'associated with atopic dermatitis. In addition, it is '
                        'developing CR845/difelikefalin Injection, which has '
                        'completed Phase II/III clinical trial for the '
                        'treatment of acute post-operative pain. The company '
                        'has license agreements with Maruishi Pharmaceutical '
                        'Co., Ltd to develop, manufacture, and commercialize '
                        'drug products containing CR845/difelikefalin for '
                        'acute pain and uremic pruritus in Japan; and Chong '
                        'Kun Dang Pharmaceutical Corporation to develop, '
                        'manufacture, and commercialize drug products '
                        'containing CR845/difelikefalin in South Korea. Cara '
                        'Therapeutics, Inc. was founded in 2004 and is '
                        'headquartered in Stamford, Connecticut.',
 'longName': 'Cara Therapeutics, Inc.',
 'market': 'us_market',
 'marketCap': 802319168,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_23340079',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -113335000,
 'nextFiscalYearEnd': 1640908800,
 'open': 17.52,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '203 406 3700',
 'previousClose': 17.63,
 'priceHint': 2,
 'priceToBook': 4.99272,
 'priceToSalesTrailing12Months': 34.000896,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 17.52,
 'regularMarketDayLow': 16.85,
 'regularMarketOpen': 17.52,
 'regularMarketPreviousClose': 17.63,
 'regularMarketPrice': 17.52,
 'regularMarketVolume': 380173,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 46796100,
 'sharesPercentSharesOut': 0.0857,
 'sharesShort': 4011049,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 3660403,
 'shortName': 'Cara Therapeutics, Inc.',
 'shortPercentOfFloat': 0.098000005,
 'shortRatio': 7.15,
 'startDate': None,
 'state': 'CT',
 'strikePrice': None,
 'symbol': 'CARA',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -2.549,
 'twoHundredDayAverage': 15.5133095,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '2959e4f9-c48b-308c-8431-9b84f96c60e5',
 'volume': 380173,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.caratherapeutics.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '06902'}